Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Temporal lobectomy for refractory epilepsy

M R Sperling1, M J O'Connor, A J Saykin

  • 1Comprehensive Epilepsy Center, Graduate Hospital, Philadelphia, PA 19146, USA.

JAMA
|August 14, 1996
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Age-specific determinants of reduced exercise capacity in youth after heart transplant: A longitudinal cohort study.

JHLT open·2025
Same author

Understanding tumour growth variability in breast cancer xenograft models identifies PARP inhibition resistance biomarkers.

NPJ precision oncology·2024
Same author

Onboarding of siponimod in secondary progressive multiple sclerosis patients in Australia: Novel, real-world evidence from the MSGo digital support programme.

Multiple sclerosis journal - experimental, translational and clinical·2024
Same author

Cardiac safety of dual anti-HER2 blockade with pertuzumab plus trastuzumab in early HER2-positive breast cancer in the APHINITY trial.

ESMO open·2023
Same author

Guidelines for the peri-operative management of people with cardiac implantable electronic devices: Guidelines from the British Heart Rhythm Society.

Anaesthesia·2022
Same author

Editorial: How Will Aducanumab Approval Impact AD Research?

The journal of prevention of Alzheimer's disease·2021
Same journal

Deescalation, Discontinuation, and Deimplementation Trials: Evaluating Whether and How to Do Less.

JAMA·2026
Same journal

Surgical and Endoscopic Therapies for GERD.

JAMA·2026
Same journal

The Psychedelic Therapies Executive Order: On Approval and Clinical Readiness.

JAMA·2026
Same journal

"Suturing": Love, Death, and Perfection's Limits.

JAMA·2026
Same journal

What Is Low Back Pain?

JAMA·2026
Same journal

From Silicon Valley to the Vatican-The Expanding Debate on AI Ethics.

JAMA·2026
See all related articles

Anterior temporal lobectomy offers sustained seizure control for most epilepsy patients over five years. Early seizure outcomes, particularly within two years, predict long-term success and improved employment.

Area of Science:

  • Neurosurgery
  • Epilepsy Management
  • Clinical Outcomes Research

Background:

  • Refractory epilepsy poses significant challenges to patient quality of life.
  • Anterior temporal lobectomy (ATL) is a surgical option for drug-resistant epilepsy.
  • Long-term effectiveness data for ATL are crucial for clinical decision-making.

Purpose of the Study:

  • To evaluate the long-term (5-year) efficacy of ATL for refractory epilepsy.
  • To assess seizure control, medical, and psychosocial outcomes post-ATL.
  • To identify predictors of long-term prognosis based on early seizure recurrence patterns.

Main Methods:

  • Prospective cohort study of 89 patients with medically refractory epilepsy.
  • Patients underwent ATL between 1986 and 1990 at a comprehensive epilepsy center.

Related Experiment Videos

  • Follow-up included seizure frequency, neuropsychological function, mortality, and employment status over 5 years.

    • Main Results:

    • 70% of patients were seizure-free at 5 years post-ATL; outcomes remained stable.
    • 55% of seizure recurrences occurred within 6 months, 93% within 2 years.
    • No significant cognitive/linguistic deficits; reduced mortality and increased employment in seizure-free patients.

    Conclusions:

    • ATL provides sustained seizure relief for the majority of patients.
    • Early seizure control (within 2 years) is a strong predictor of long-term outcomes.
    • Achieving a seizure-free state post-ATL is linked to improved mortality and employment rates.